跳至主要内容
临床试验/NCT06840509
NCT06840509进行中(未招募)不适用

BIO|CONCEPT.CorSky Family, First in Human Study for the CorSky ICD Family

Biotronik Australia Pty Ltd.1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2025年7月23日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
52
试验地点
1
主要终点
Serious adverse device effect (SADE)-free rate after 12 months

研究概览

简要总结

The goal of this exploratory study is to test the preliminary safety and product performance of the new CorSky ICD family in subjects that require an ICD or cardiac resynchronization therapy with defibrillation (CRT-D). The study will be conducted at sites in Australia and New Zealand. It is planned to include 50 subjects in the study. Participants will visit sites at enrollment in the study, at implantation, pre-hospital discharge, 1- 3- and 12-month follow-up visits. At the visits the device will be interrogated and standard device measurements including those related to special features will be performed to assess the functionality of the device. Programming of the ICDs will be done according to the participant´s therapeutical needs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Standard indication for ICD or CRT-D therapy according to clinical guidelines
  • Planned for de novo implantation of an ICD/CRT-D, or upgrade/exchange from existing ICD/CRT-D or pacemaker implant
  • Ability to understand the nature of the study
  • Willingness to provide written informed consent
  • Ability and willingness to perform all on-site follow-up visits at the study site Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept

排除标准

  • For VR-T DX and CRT-DX: Permanent atrial tachyarrhythmia
  • For VR-T DX and CRT-DX: Patients requiring atrial pacing
  • Planned for His-Bundle-Pacing
  • Planned cardiac surgical procedures or interventional measures other than the study procedure within the next 12 months
  • Pregnant or breast feeding
  • Age less than 18 years
  • Participation in another interventional clinical investigation according to the definition given below 2,3
  • Life-expectancy less than 12 months

研究组 & 干预措施

Patients with indication for ICD or CRT-D therapy according to standard clinical guidelines.

Experimental

干预措施: CorSky ICD or CRT-D (Device)

结局指标

主要结局

Serious adverse device effect (SADE)-free rate after 12 months

时间窗: 12 months

Descriptive statistics of the investigational device related SADE-free rate after first implantation attempt will be calculated using a Kaplan-Meier estimate

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

BIO|CONCEPT.CorSky, First in Human Study for the... | 临床试验